OTC Markets OTCPK - Delayed Quote USD

Innovent Biologics, Inc. (IVBXF)

Compare
5.08 -0.17 (-3.24%)
At close: October 28 at 4:00 PM EDT
Loading Chart for IVBXF
DELL
  • Previous Close 5.25
  • Open 5.25
  • Bid 5.00 x 40000
  • Ask 6.21 x 40000
  • Day's Range 5.25 - 5.25
  • 52 Week Range 3.83 - 6.41
  • Volume 700
  • Avg. Volume 8,666
  • Market Cap (intraday) 8.272B
  • Beta (5Y Monthly) 0.12
  • PE Ratio (TTM) --
  • EPS (TTM) -0.11
  • Earnings Date Aug 28, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

www.innoventbio.com

5,263

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IVBXF

View More

Performance Overview: IVBXF

Trailing total returns as of 10/29/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

IVBXF
3.25%
HANG SENG INDEX
21.43%

1-Year Return

IVBXF
14.48%
HANG SENG INDEX
18.98%

3-Year Return

IVBXF
44.66%
HANG SENG INDEX
19.00%

5-Year Return

IVBXF
58.26%
HANG SENG INDEX
23.02%

Compare To: IVBXF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IVBXF

View More

Valuation Measures

Annual
As of 10/28/2024
  • Market Cap

    8.11B

  • Enterprise Value

    7.39B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.78

  • Price/Book (mrq)

    4.74

  • Enterprise Value/Revenue

    7.06

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -17.18%

  • Return on Assets (ttm)

    -4.18%

  • Return on Equity (ttm)

    -11.04%

  • Revenue (ttm)

    7.46B

  • Net Income Avi to Common (ttm)

    -1.28B

  • Diluted EPS (ttm)

    -0.11

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.63B

  • Total Debt/Equity (mrq)

    26.95%

  • Levered Free Cash Flow (ttm)

    -176.4M

Company Insights: IVBXF

People Also Watch